CD47 and metastatic neoplasm: TME remodelling by engineered OMVs or IR700‐loaded engineered OMVs‐mediated photoimmunotherapy resulted in increased recruitment and activation of TAMs and the M1 phenotype, synergistically maximising antitumour efficacy with CD47 blocking therapies in primary and metastatic tumour models.